Skip to main content
. Author manuscript; available in PMC: 2022 Jul 5.
Published in final edited form as: Eur J Med Chem. 2021 Apr 4;219:113425. doi: 10.1016/j.ejmech.2021.113425

Figure 1.

Figure 1.

Design of MDM2 degraders. (A) Structure of MDM2 degrader WB156, Ugi ligands 1 and 2; (B) Co-crystal structure of Ugi ligand bound to the MDM2 binding site (PDB code: 3TJ2); (C) The strategy to construct MDM2 degraders from ligands derived from Ugi reaction and lenalidomide derivative.